ISOLATED MYELOSARCOMA TREATED AS AML, WITH PROGRESSION TO MDS/MPN

被引：0
|
作者：
Fuentes, A. [1 ]
LaBier, G. [2 ]
Boulmay, B. [1 ]
机构：
[1] LSU Hlth Sci Ctr, Metairie, LA USA
[2] LSU, New Orleans, LA USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2018年 / 66卷 / 02期
关键词：
D O I：
10.1136/jim-2017-000697.217
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
217
引用
收藏
页码：440 / 440
页数：1
相关论文
共 50 条
  • [31] Isolated myelosarcoma in children - Update and review
    Reinhardt, D
    Creutzig, U
    LEUKEMIA & LYMPHOMA, 2002, 43 (03) : 565 - 574
  • [32] Recurrent transcriptional responses in AML and MDS patients treated with decitabine
    Upadhyay, Pawan
    Beales, Jeremy
    Shah, Nakul M.
    Gruszczynska, Agata
    Miller, Christopher A.
    Petti, Allegra A.
    Ramakrishnan, Sai Mukund
    Link, Daniel C.
    Ley, Timothy J.
    Welch, John S.
    EXPERIMENTAL HEMATOLOGY, 2022, 111 : 50 - 65
  • [33] AML / MDS
    Bone Marrow Transplantation, 2002, 29 (Suppl 2) : S54 - S57
  • [34] AML and MDS treated with nonmyeloablative stem cell transplantation: Overall and progression free survival comparable to myeloablative transplantation.
    Alyea, EP
    Kim, HT
    Cutler, C
    Ho, V
    Lee, SJ
    Parik, B
    Windawi, S
    DeAngelo, D
    Stone, RM
    Ritz, J
    Antin, JH
    Soiffer, RJ
    BLOOD, 2003, 102 (11) : 79A - 79A
  • [35] THE MDS/MPN PATIENTS TREATED WITH 5-AZACITIDINE: A CLINICAL REAL LIFE EXPERIENCE
    Riva, M.
    Molteni, A.
    Borin, L.
    Bernardi, M.
    Pellizzari, A.
    Freyrie, A.
    Della Porta, M.
    Nichelatti, M.
    Ravano, E.
    Quaresmini, G.
    Mariotti, J.
    Caramazza, D.
    Ubezio, M.
    Guarco, S.
    Gigli, F.
    Greco, R.
    Cairoli, R.
    HAEMATOLOGICA, 2015, 100 : 725 - 725
  • [36] MYC overexpression is associated with an early disease progression from MDS to AML
    Gajzer, David
    Logothetis, Constantine N.
    Sallman, David A.
    Calon, Gregoire
    Babu, Abida
    Chan, Onyee
    Vincelette, Nicole D.
    Volpe, Virginia O.
    Al Ali, Najla H.
    Basra, Pukhraz
    Talati, Chetasi
    Kuykendall, Andrew T.
    Mo, Qianxing
    Padron, Eric
    Sweet, Kendra
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    Yun, Seongseok
    Zhang, Ling
    LEUKEMIA RESEARCH, 2021, 111
  • [37] 5q Deletions in MDS and MPN: The Accompanying Molecular Mutations Determine the Phenotype but TP53 Is Frequently Mutated in All Entities: MPN, MDS and MPN/MDS Overlap
    Haferlach, Claudia
    Meggendorfer, Manja
    Schnittger, Susanne
    Zenger, Melanie
    Kern, Wolfgang
    Haferlach, Torsten
    BLOOD, 2014, 124 (21)
  • [38] Real-world outcomes in patients with AML and MDS treated with Azacitidine
    Prusak, E.
    Lawes, M.
    Collins, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 42 - 42
  • [39] Genomics of MPN progression
    Patel, Anand A.
    Odenike, Olatoyosi
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 440 - 449
  • [40] Prognostic factors associated with progression of myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) in patients (pts) treated with decitabine.
    Fullmer, A.
    Borthakur, G.
    Kadia, T. M.
    Garcia-Manero, G.
    Jabbour, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345